ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    oph2003
Previous Study | Return to List | Next Study

Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02686658
Recruitment Status : Active, not recruiting
First Posted : February 19, 2016
Last Update Posted : November 9, 2018
Sponsor:
Information provided by (Responsible Party):
Ophthotech Corporation

Brief Summary:
The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura when administered in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Geographic Atrophy Macular Degeneration Drug: Zimura Other: Sham Phase 2

Detailed Description:

Part 1: Approximately 66 subjects will be randomized in a 1:1:1 ratio to the following dose groups:

  • Zimura Dose Administration 1
  • Zimura Dose Administration 2
  • Sham Administration 1

Part 2: Approximately 135 subjects will be randomized in a 1:2:2 ratio to the following dose groups:

  • Zimura Dose Administration 3
  • Zimura Dose Administration 4
  • Sham Administration 2

Subjects will receive monthly intravitreal injections of Zimura or Sham for 18 months.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Actual Study Start Date : January 2016
Estimated Primary Completion Date : November 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dose Group 1
Zimura Dose Administration 1
Drug: Zimura
Zimura Dose Administration 1
Other Name: avacincaptad pegol

Experimental: Dose Group 2
Zimura Dose Administration 2
Drug: Zimura
Zimura Dose Administration 2
Other Name: avaincaptad pegol

Sham Comparator: Dose Group 3
Sham Administration 1
Other: Sham
Sham Administration 1

Experimental: Dose Group 4
Zimura Dose Administration 3
Drug: Zimura
Zimura Dose Administration 3
Other Name: avacincaptad pegol

Experimental: Dose Group 5
Zimura Dose Administration 4
Drug: Zimura
Zimura Dose Administration 4
Other Name: avacincaptad pegol

Sham Comparator: Dose Group 6
Sham Administration 2
Other: Sham
Sham Administration 2




Primary Outcome Measures :
  1. Change in geographic atrophy (GA) [ Time Frame: 12 months ]
    Mean rate of change in GA measured by fundus autofluorescence (FAF)


Secondary Outcome Measures :
  1. Best Corrected Visual Acuity (BCVA) [ Time Frame: 12 months ]
    Mean change in BCVA (Early Treatment Diabetic Retinopathy Study [ETDRS] letter)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects of either gender aged ≥ 50 years
  • Diagnosis of Non-foveal GA secondary to dry AMD

Exclusion Criteria:

  • Evidence of Choroidal Neovascularization (CNV)
  • GA secondary to any condition other than AMD
  • Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals
  • Any intraocular surgery or thermal laser within three (3) months of trial entry
  • Any prior thermal laser in the macular region, regardless of indication
  • Any ocular or periocular infection in the twelve (12) weeks
  • Previous therapeutic radiation in the region of the study eye
  • Any sign of diabetic retinopathy in either eye

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02686658


  Show 78 Study Locations
Sponsors and Collaborators
Ophthotech Corporation

Responsible Party: Ophthotech Corporation
ClinicalTrials.gov Identifier: NCT02686658     History of Changes
Other Study ID Numbers: OPH2003
First Posted: February 19, 2016    Key Record Dates
Last Update Posted: November 9, 2018
Last Verified: July 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ophthotech Corporation:
Geographic Atrophy (GA)
Dry age-related macular degeneration
AMD
Zimura
Anti-inflammatory
complement factor C5 inhibitor
ARC1905
avacincaptad pegol

Additional relevant MeSH terms:
Macular Degeneration
Atrophy
Geographic Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pathological Conditions, Anatomical